Information Provided By: 
Fly News Breaks for October 1, 2019
GHDX, EXAS
Oct 1, 2019 | 08:07 EDT
Jefferies analyst Brandon Couillard believes the recent weakness in shares of Exact Sciences (EXAS) offers an attractive entry point. After hosting investor meetings with management, the analyst is more confident in the long-term strategic benefits of the Genomic Health (GHDX) acquisition, the long-term growth runway left for Cologuard, and catalysts for sustained momentum in 2020. He sees potential upside to second half of 2019 consensus estimates and keeps a Buy rating on Exact Sciences with a $138 price target.
News For EXAS;GHDX From the Last 2 Days
There are no results for your query EXAS;GHDX
